Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Market Outlook
Thelansis’s “Recurrent or Metastatic
Head and Neck Squamous Cell Carcinoma Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2024 To 2034" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Recurrent
or Metastatic Head and Neck Squamous Cell Carcinoma treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Recurrent or Metastatic Head and Neck
Squamous Cell Carcinoma Overview
Head and
neck squamous cell carcinoma (HNSCC) stands as the prevailing cancer
originating within the head and neck area, predominantly influenced by factors
such as smoking, excessive alcohol consumption, and human papillomavirus (HPV)
infection. Despite treatments, recurrent or metastatic cases of SCCHN typically
exhibit a bleak prognosis, with a median survival of around 12 months.
Significant advancements have been made in managing recurrent or metastatic
SCCHN in recent years. However, outcomes remain subpar, particularly with
systemic therapy alone, trailing behind outcomes for other solid tumors. A
considerable portion of HNSCC patients facing recurrence or metastasis continue
to experience poor survival rates. Consequently, there has been a concerted
effort to explore novel biomarkers and therapies based on biomarker analysis.
HPV infection has emerged as a primary causal factor for HNSCC, notably in the
oropharynx (OPSCC), which accounts for approximately 60–70% of cases in the
United States.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment